Last reviewed · How we verify

TABLICAPS — Portfolio Competitive Intelligence Brief

TABLICAPS pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Estrobene DIETHYLSTILBESTROL marketed Standardized Chemical Allergen [EPC] Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3 Pain 1973-01-01

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. · 1 shared drug class
  2. Deseret Biologicals, Inc. · 1 shared drug class
  3. Donat R. Spahn · 1 shared drug class
  4. Dr. Laurence Klotz · 1 shared drug class
  5. Marjan Industria e Comercio ltda · 1 shared drug class
  6. Millet Roux · 1 shared drug class
  7. Nantes University Hospital · 1 shared drug class
  8. Nutritional Specialties, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for TABLICAPS:

Cite this brief

Drug Landscape (2026). TABLICAPS — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tablicaps. Accessed 2026-06-10.

Related